Developer docs
API playgroundTry for free, no card

Search company profiles

Singular Genomics

Full company profile

uuid0000hb1

Namestring
Singular Genomics
Legal namestring
Singular Genomics Systems, Inc.
Company typeenum
Private
Founded yearint
2016
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersSan Diego, United States
HQ citystring
San Diego
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
spatial multiomics platforms, next-generation sequencing instruments, in situ transcriptomics, FFPE tissue analysis, genomic research reagents
Industry5 codes
PRIMARYHLAGANAC
Single-Cell & Spatial Omics Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Specialty Lab Services (Genomics/Proteomics/Cellomics)
SECONDARYHLAGAJAD
Bioinformatics & Multi-omics Analysis Software
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAGAIAF
Molecular Biology & Genomics Instruments (PCR/qPCR, Sequencing, Microarrays)
SECONDARYHLAGANAI
Bioinformatics, Multi-Omics Data Analysis & Interpretation Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Specialty Lab Services (Genomics/Proteomics/Cellomics)
SECONDARYHLAGAEAD
Genomics & Molecular Diagnostics (Trial Support)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Central Labs & Clinical Diagnostics Services (Trial Support)
NAICS code4 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
  • Medical and Diagnostic Laboratories6215
  • Medical Laboratories621511
SIC code2 codes
  • Laboratory Analytical Instruments3826
  • Services-Commercial Physical & Biological Research8731
Product category
Genomics and Spatial Multiomics Instruments
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model4 records
1G4X Spatial Sequencer Instruments
TypeHardware Sales
Description

Sale of the G4X Spatial Sequencer instrument to research institutions, academic medical centers, and biopharma. Instrument sold with 12-month initial support services included.

singulargenomics.com
2Consumables and Reagents
TypeHardware Sales
Description

Proprietary reagents, kits, and tools designed for use with the G4X instrument including spatial transcriptomics kits, multiomics kits, and custom panels. Consumables are single-use and must be repurchased for each run.

singulargenomics.com
3Product Services and Support
TypeSubscription Recurring
Description

Support services including on-site support, software and instrument support, preventative maintenance, and validation. Initial 12-month support included with instrument purchase; extended warranty and service plans available for purchase.

singulargenomics.com
4Professional Services
TypeProfessional Services
Description

Custom content design services and professional services for sample processing and data analysis. Custom G4X Panels designed to target customer-specified molecules.

singulargenomics.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain
Pricing details3 tiers
1G4X Spatial Sequencer instrument with integrated multiomics capabilities
ModelOne time/ perpetual licenseBilling cadenceMulti-year contract
Notes

Commercial platform available for purchase in the United States following successful early access program. Includes 12-month initial support services.

singulargenomics.com
2Spatial analysis from $240 per sample
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Per-sample costs in the low hundreds represents significant cost reduction compared to traditional spatial biology methods. Sample-to-answer workflow completed in 5 days.

singulargenomics.com
3Technology Access Services
ModelUsage-basedBilling cadencePay-as-you-go
Notes

Available for researchers wishing to generate multiomic data without instrument purchase. Supports 25+ unique technology access projects.

singulargenomics.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Singular Genomics develops and sells the G4X Spatial Sequencer, a high-throughput in situ multiomics platform that performs simultaneous spatial transcriptomics (up to 1,300-plex RNA), 18-plex proteomics, and morphological (fH&E) analysis on a single FFPE tissue section at subcellular resolution, processing up to 128 samples per run. The company also sells the G4 benchtop next-generation sequencing platform plus proprietary consumables (spatial kits, RNA/protein panels, Direct-Seq reagents, TissuStamp tooling) and Spatial Services for technology access and support, targeting academic medical centers, research institutions, and biopharmaceutical customers.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Nearly 20,000 FFPE samples processed and approximately 4 billion spatially resolved single cells profiled across dozens of sample types
+3 more records
Product overview1 text field

Singular Genomics offers a platform-plus-modules architecture centered on two core products: the G4X Spatial Sequencer and the G4 Sequencing Platform. The G4X is a high-throughput spatial multiomics platform that delivers simultaneous RNA, protein, and morphology analysis from FFPE tissue samples, while the G4 is a benchtop NGS sequencer for traditional sequencing workflows. The portfolio includes supporting kits (X2/X4 Spatial Transcriptomics and Multiomics Kits), consumables (RNA and Protein Panels), library prep adapters and primers, Direct-Seq in situ sequencing modules, TissuStamp tooling, and Spatial Services. The products share a unified ecosystem designed for translational research, clinical applications, and large-scale spatial biology studies.

Product and service8 records
1G4X Spatial Sequencer
CategoryGenomics instruments
Description

High-throughput in situ spatial multiomics platform that performs simultaneous RNA, protein, and fH&E morphological analysis on a single FFPE tissue section at subcellular resolution; processes up to 128 samples per run with approximately 40 cm² of imaging area. Sold to academic medical centers, research institutions, and biopharma customers in the United States, with 12-month initial support bundled.

2G4 Sequencing Platform
CategoryGenomics instruments
Description

Benchtop next-generation sequencer providing fast and accurate NGS results, compatible with a wide range of third-party library preparation products (10x Genomics, Agilent, IDT, NEB, Roche, etc.) through SG Universal Library Prep Adapter and SG UDI Primers.

3Spatial Services
CategoryServices
Description

Professional services offering technology access programs, training, and support for the G4X platform, enabling researchers to generate multiomic data without instrument purchase; also includes custom panel design and sample/data analysis services for translational and clinical applications.

4X2 and X4 Spatial Transcriptomics Kit
CategoryConsumables and reagents
Description

Proprietary spatial transcriptomics kit for gene expression profiling with spatial context, part of the spatial multiomics workflow on the G4 and G4X platforms; consumable requiring repurchase for each run.

5X2 and X4 Spatial Multiomics Kit
CategoryConsumables and reagents
Description

Proprietary spatial multiomics kit enabling simultaneous profiling of RNA and protein from tissue samples with spatial resolution on the G4 and G4X platforms; consumable requiring repurchase for each run.

6RNA Panels for G4X
CategoryConsumables and reagents
Description

Targeted RNA panels for the G4X platform including tissue-specific panels (lung, kidney, colon, breast) with immune-oncology focus, available in plex levels up to 1,300 genes for use with the G4X Spatial Sequencer.

7Protein Panels for G4X
CategoryConsumables and reagents
Description

Multiplexed protein detection panels for the G4X platform enabling simultaneous protein expression analysis alongside RNA profiling on the same FFPE section.

8Direct-Seq In Situ Sequencing
CategoryConsumables and reagents
Description

In situ sequencing technology enabling sequencing of variable regions within cells in FFPE tissue, supporting T- and B-cell receptor (immune repertoire) sequencing and somatic mutation profiling at subcellular resolution; Early Access planned for H2 2026.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
1Vanderbilt University Medical Center
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2026-03-18
Description

Center of Excellence collaboration deploying G4X Spatial Sequencer in support of HTAN's Pre-Gastric Cancer program (GAME3D). Aims to enable scalable, cost-efficient spatial multimodal profiling for building comprehensive 3D atlases of gastric disease progression from precancerous lesions to malignancy. G4X provides integrated in situ readouts combining 1,000-plex RNA, 18-plex protein, and fH&E at subcellular resolution.

prnewswire.com
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2026-03-12
Description

Designation of Spatial Technologies Unit (STU) at BIDMC as G4X Center of Excellence. STU is first G4X Early Access Program site and a DF/HCC Core Facility. Partnership will share best-practice workflows from tissue preparation to data QC, study design, and downstream analysis to help researchers run reproducible G4X studies at scale.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2025-07-01
Description

Collaboration announced July 2025 to develop customized NGS reagent kits. Partnership aims to enhance automation in genomics workflows amidst rising US demand for diagnostics and personalized medicine. Tecan is a Swiss lab automation leader.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

SPOT-Met (Spatial Predictors Of Tropism and Metastasis) initiative - a 1,000-tumor colorectal cancer program described as perhaps the world's largest colorectal cancer spatial multiomics initiative. Will leverage G4X platform for spatial multiomics profiling linking spatial readouts to clinical and molecular annotation to advance understanding of metastatic behavior.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Developer of the Molecular Cartography platform for subcellular spatial multiomics. Direct competitor in high-plex in situ spatial analysis; notably, current Singular CEO John Stark previously led Resolve Biosciences, indicating close technology and customer overlap.

TypeDirect peer
Description

Direct competitor in spatial transcriptomics and in situ analysis, offering Visium, Visium HD, and Xenium platforms. Most well-funded and commercially scaled rival; comparable target customers (AMCs, biopharma) and similar spatial biology value proposition.

TypeEmerging player
Description

Provider of RNAscope in situ hybridization assays and the recently launched Advanced Cell Diagnostics spatial products. Comparable in the spatial transcriptomics reagent market and shares academic and translational research customers.

TypeDirect peer
Description

Provider of the PhenoCycler (formerly CODEX) spatial proteomics platform and Opal multiplexed imaging reagents. Competes in the spatial biology market with a proteomics-led offering rather than transcriptomics, but addresses the same translational research and biopharma biomarker customers.

TypeBroad incumbent
Description

Largest incumbent in next-generation sequencing with NovaSeq, NextSeq, and MiSeq platforms. Competes indirectly through sequencing customers who may default to Illumina for spatial workflows rather than adopting the G4 benchtop sequencer.

TypeDirect peer
Description

Developer of the MERFISH-based spatial transcriptomics platform. Closely comparable technology (in situ spatial transcriptomics with subcellular resolution), targeting similar academic and translational research customers.

TypeEmerging player
Description

Developer of the Orion spatial biology platform combining cyclic immunofluorescence with RNA in situ hybridization. Emerging competitor in the spatial multiomics space targeting similar AMC and translational customers.

TypeEmerging player
Description

Developer of the AVITI benchtop NGS sequencer competing with Singular's G4 platform in the broader next-generation sequencing market. Less direct overlap on spatial multiomics but competes on the same sequencing-instrument purchase decisions.

TypeOthers
Description

Swiss lab automation leader partnering with Singular Genomics (July 2025) to develop customized NGS reagent kits. Comparable as an adjacent automation partner for genomics workflows and potential competitor in workflow integration.

TypeDirect peer
Description

Acquired NanoString's spatial biology assets including GeoMx digital spatial profiling and CosMx spatial molecular imager. Direct competitor in spatial multiomics with overlapping AMC and translational research customers.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers7 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration16 records

Each record includes

Title, Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles9 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors11 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Singular Genomics

Genomics and Spatial Multiomics Instrumentssingulargenomics.com

Singular Genomics firmographics

Firmographics
Name
Singular Genomics
Legal name
Singular Genomics Systems, Inc.
Website
https://singulargenomics.com
Company type
Private
Founded year
2016
Operating status
Operating
Headcount range
101–250 employees
Ownership category
akta.pro rank

Singular Genomics industry classification

Industry
Product category
Genomics and Spatial Multiomics Instruments
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417), Medical and Diagnostic Laboratories (6215), Medical Laboratories (621511)
SIC
Laboratory Analytical Instruments (3826), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAGANAC
Single-Cell & Spatial Omics Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Specialty Lab Services (Genomics/Proteomics/Cellomics)
SECONDARYHLAGAJAD
Bioinformatics & Multi-omics Analysis Software
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAGAIAF
Molecular Biology & Genomics Instruments (PCR/qPCR, Sequencing, Microarrays)
SECONDARYHLAGANAI
Bioinformatics, Multi-Omics Data Analysis & Interpretation Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Specialty Lab Services (Genomics/Proteomics/Cellomics)
SECONDARYHLAGAEAD
Genomics & Molecular Diagnostics (Trial Support)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Central Labs & Clinical Diagnostics Services (Trial Support)

Keywords

  • Spatial multiomics platforms
  • Next-generation sequencing instruments
  • In situ transcriptomics
  • FFPE tissue analysis
  • Genomic research reagents

Where Singular Genomics is headquartered

Location

Headquarters

HQ city
San Diego
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Singular Genomics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

  1. G4X Spatial Sequencer Instruments: Sale of the G4X Spatial Sequencer instrument to research institutions, academic medical centers, and biopharma. Instrument sold with 12-month initial support services included.
  2. Consumables and Reagents: Proprietary reagents, kits, and tools designed for use with the G4X instrument including spatial transcriptomics kits, multiomics kits, and custom panels. Consumables are single-use and must be repurchased for each run.
  3. Product Services and Support: Support services including on-site support, software and instrument support, preventative maintenance, and validation. Initial 12-month support included with instrument purchase; extended warranty and service plans available for purchase.
  4. Professional Services: Custom content design services and professional services for sample processing and data analysis. Custom G4X Panels designed to target customer-specified molecules.

Pricing tiers

ModelBillingPrice
One time/ perpetual licenseMulti-year contractG4X Spatial Sequencer instrument with integrated multiomics capabilities
Unit PricingPay-as-you-goSpatial analysis from $240 per sample
Usage-basedPay-as-you-goTechnology Access Services

Go-to-market motion2 records

Distribution channels2 records

Marketing channels6 records

Singular Genomics product offering

Product offering

Core offering

Singular Genomics develops and sells the G4X Spatial Sequencer, a high-throughput in situ multiomics platform that performs simultaneous spatial transcriptomics (up to 1,300-plex RNA), 18-plex proteomics, and morphological (fH&E) analysis on a single FFPE tissue section at subcellular resolution, processing up to 128 samples per run. The company also sells the G4 benchtop next-generation sequencing platform plus proprietary consumables (spatial kits, RNA/protein panels, Direct-Seq reagents, TissuStamp tooling) and Spatial Services for technology access and support, targeting academic medical centers, research institutions, and biopharmaceutical customers.

Product overview

Singular Genomics offers a platform-plus-modules architecture centered on two core products: the G4X Spatial Sequencer and the G4 Sequencing Platform. The G4X is a high-throughput spatial multiomics platform that delivers simultaneous RNA, protein, and morphology analysis from FFPE tissue samples, while the G4 is a benchtop NGS sequencer for traditional sequencing workflows. The portfolio includes supporting kits (X2/X4 Spatial Transcriptomics and Multiomics Kits), consumables (RNA and Protein Panels), library prep adapters and primers, Direct-Seq in situ sequencing modules, TissuStamp tooling, and Spatial Services. The products share a unified ecosystem designed for translational research, clinical applications, and large-scale spatial biology studies.

Differentiator

Problem solved

Functional benefit

Products and services

  • G4X Spatial Sequencer High-throughput in situ spatial multiomics platform that performs simultaneous RNA, protein, and fH&E morphological analysis on a single FFPE tissue section at subcellular resolution; processes up to 128 samples per run with approximately 40 cm² of imaging area. Sold to academic medical centers, research institutions, and biopharma customers in the United States, with 12-month initial support bundled.
  • G4 Sequencing Platform Benchtop next-generation sequencer providing fast and accurate NGS results, compatible with a wide range of third-party library preparation products (10x Genomics, Agilent, IDT, NEB, Roche, etc.) through SG Universal Library Prep Adapter and SG UDI Primers.
  • Spatial Services Professional services offering technology access programs, training, and support for the G4X platform, enabling researchers to generate multiomic data without instrument purchase; also includes custom panel design and sample/data analysis services for translational and clinical applications.
  • X2 and X4 Spatial Transcriptomics Kit Proprietary spatial transcriptomics kit for gene expression profiling with spatial context, part of the spatial multiomics workflow on the G4 and G4X platforms; consumable requiring repurchase for each run.
  • X2 and X4 Spatial Multiomics Kit Proprietary spatial multiomics kit enabling simultaneous profiling of RNA and protein from tissue samples with spatial resolution on the G4 and G4X platforms; consumable requiring repurchase for each run.
  • RNA Panels for G4X Targeted RNA panels for the G4X platform including tissue-specific panels (lung, kidney, colon, breast) with immune-oncology focus, available in plex levels up to 1,300 genes for use with the G4X Spatial Sequencer.
  • Protein Panels for G4X Multiplexed protein detection panels for the G4X platform enabling simultaneous protein expression analysis alongside RNA profiling on the same FFPE section.
  • Direct-Seq In Situ Sequencing In situ sequencing technology enabling sequencing of variable regions within cells in FFPE tissue, supporting T- and B-cell receptor (immune repertoire) sequencing and somatic mutation profiling at subcellular resolution; Early Access planned for H2 2026.

Quantifiable outcome

  • Nearly 20,000 FFPE samples processed and approximately 4 billion spatially resolved single cells profiled across dozens of sample types
  • +3 more outcomes

Companies that use Singular Genomics

Customer profile

Named customers7 records

Segments4 records

Ideal customer profiles3 records

Singular Genomics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration16 records

Feature5 records

Singular Genomics partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered flagship and core.

  • Vanderbilt University Medical CenterflagshipStrategic or Co-development Partner · 18 March 2026Center of Excellence collaboration deploying G4X Spatial Sequencer in support of HTAN's Pre-Gastric Cancer program (GAME3D). Aims to enable scalable, cost-efficient spatial multimodal profiling for building comprehensive 3D atlases of gastric disease progression from precancerous lesions to malignancy. G4X provides integrated in situ readouts combining 1,000-plex RNA, 18-plex protein, and fH&E at subcellular resolution.
  • Beth Israel Deaconess Medical Center (Spatial Technologies Unit)flagshipStrategic or Co-development Partner · 12 March 2026Designation of Spatial Technologies Unit (STU) at BIDMC as G4X Center of Excellence. STU is first G4X Early Access Program site and a DF/HCC Core Facility. Partnership will share best-practice workflows from tissue preparation to data QC, study design, and downstream analysis to help researchers run reproducible G4X studies at scale.
  • Tecan Group AGcoreTechnology or Integration · 1 July 2025Collaboration announced July 2025 to develop customized NGS reagent kits. Partnership aims to enhance automation in genomics workflows amidst rising US demand for diagnostics and personalized medicine. Tecan is a Swiss lab automation leader.
  • Weill Cornell MedicinecoreStrategic or Co-development PartnerSPOT-Met (Spatial Predictors Of Tropism and Metastasis) initiative - a 1,000-tumor colorectal cancer program described as perhaps the world's largest colorectal cancer spatial multiomics initiative. Will leverage G4X platform for spatial multiomics profiling linking spatial readouts to clinical and molecular annotation to advance understanding of metastatic behavior.

Scale indicators7 records

Recent moves7 records

Expansion highlights6 records

Singular Genomics competitors and assessment

Company assessment

Direct peers

  • Resolve Biosciences: Developer of the Molecular Cartography platform for subcellular spatial multiomics. Direct competitor in high-plex in situ spatial analysis; notably, current Singular CEO John Stark previously led Resolve Biosciences, indicating close technology and customer overlap.
  • 10x Genomics: Direct competitor in spatial transcriptomics and in situ analysis, offering Visium, Visium HD, and Xenium platforms. Most well-funded and commercially scaled rival; comparable target customers (AMCs, biopharma) and similar spatial biology value proposition.
  • Akoya Biosciences: Provider of the PhenoCycler (formerly CODEX) spatial proteomics platform and Opal multiplexed imaging reagents. Competes in the spatial biology market with a proteomics-led offering rather than transcriptomics, but addresses the same translational research and biopharma biomarker customers.
  • Vizgen: Developer of the MERFISH-based spatial transcriptomics platform. Closely comparable technology (in situ spatial transcriptomics with subcellular resolution), targeting similar academic and translational research customers.
  • Bruker (NanoString spatial business): Acquired NanoString's spatial biology assets including GeoMx digital spatial profiling and CosMx spatial molecular imager. Direct competitor in spatial multiomics with overlapping AMC and translational research customers.

Emerging players

  • Bio-Techne: Provider of RNAscope in situ hybridization assays and the recently launched Advanced Cell Diagnostics spatial products. Comparable in the spatial transcriptomics reagent market and shares academic and translational research customers.
  • RareCyte: Developer of the Orion spatial biology platform combining cyclic immunofluorescence with RNA in situ hybridization. Emerging competitor in the spatial multiomics space targeting similar AMC and translational customers.
  • Element Biosciences: Developer of the AVITI benchtop NGS sequencer competing with Singular's G4 platform in the broader next-generation sequencing market. Less direct overlap on spatial multiomics but competes on the same sequencing-instrument purchase decisions.

Broad incumbents

  • Illumina: Largest incumbent in next-generation sequencing with NovaSeq, NextSeq, and MiSeq platforms. Competes indirectly through sequencing customers who may default to Illumina for spatial workflows rather than adopting the G4 benchtop sequencer.

Others

  • Tecan: Swiss lab automation leader partnering with Singular Genomics (July 2025) to develop customized NGS reagent kits. Comparable as an adjacent automation partner for genomics workflows and potential competitor in workflow integration.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Singular Genomics social profiles

Digital presence

Singular Genomics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Singular Genomics leadership team

Management profile

Number of profiles

Profiles9 records

Singular Genomics funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors11 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Singular Genomics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Singular Genomics

What does Singular Genomics do?

Singular Genomics develops and sells the G4X Spatial Sequencer, a high-throughput in situ multiomics platform that performs simultaneous spatial transcriptomics (up to 1,300-plex RNA), 18-plex proteomics, and morphological (fH&E) analysis on a single FFPE tissue section at subcellular resolution, processing up to 128 samples per run. The company also sells the G4 benchtop next-generation sequencing platform plus proprietary consumables (spatial kits, RNA/protein panels, Direct-Seq reagents, TissuStamp tooling) and Spatial Services for technology access and support, targeting academic medical centers, research institutions, and biopharmaceutical customers.

Is Singular Genomics a public or private company?

Singular Genomics is a private company. It is classified as private equity controlled and is currently operating.

When was Singular Genomics founded?

Singular Genomics was founded in 2016. It employs 101 to 250 people.

Where is Singular Genomics based?

Singular Genomics is headquartered in San Diego, United States, in the North America region.

How does Singular Genomics make money?

Four revenue lines are on record. G4X Spatial Sequencer Instruments are the primary driver. The others are consumables and Reagents, product Services and Support and professional Services.

Who are Singular Genomics's main competitors?

Direct peers on record are Resolve Biosciences, 10x Genomics, Akoya Biosciences, Vizgen and Bruker (NanoString spatial business). Emerging players are Bio-Techne, RareCyte and Element Biosciences. Illumina is listed as a broad incumbent. Tecan is listed as an others.

Does Singular Genomics have an API?

No public API is recorded for Singular Genomics.

What industry is Singular Genomics in?

Singular Genomics's product category is Genomics and Spatial Multiomics Instruments. Its primary akta.pro industry code is HLAGANAC, Single-Cell & Spatial Omics Services, with a secondary code of HLAGAJAD, Bioinformatics & Multi-omics Analysis Software. Its NAICS code is 541714 and its SIC code is 3826.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
AD HOC NEWSTecan Group AG stock (CH0012100191): Lab automation leader eyes US growthTecan Group AG, a Swiss lab automation company, announced a collaboration with US-based Singular Genomics Systems in July 2025 to develop customized NGS reagent kits. The partnership aims to enhance automation in genomics workflows amidst rising US demand for diagnostics and personalized medicine.AijournSingular Genomics Names John Stark as Chief Executive Officer as Company Builds on Spatial Platform MomentumSingular Genomics announced the appointment of John Stark as Chief Executive Officer, succeeding Josh Stahl who will transition to an Independent Director role on the Board. John Stark brings more than 25 years of experience commercializing innovative technologies, having previously led Resolve Biosciences, Quantum-Si, and Celsee. The leadership change occurs as Singular builds on the successful launch of its G4X Spatial Sequencer platform and aims to expand adoption and deepen strategic partnerships in the spatial biology and precision medicine markets.PR NewswireSingular Genomics Names John Stark as Chief Executive Officer as Company Builds on Spatial Platform MomentumSingular Genomics Systems, Inc. announced the appointment of John Stark as Chief Executive Officer, succeeding Josh Stahl who will transition to Independent Director on the Board. Stark brings over 25 years of experience commercializing innovative technologies across multiple life science companies, most recently serving as CEO of Resolve Biosciences. The company stated it is positioned to capitalize on its G4X spatial platform success and expand adoption across translational research, drug development, and clinical applications.SdbnSingular Genomics Names John Stark as Chief Executive Officer as Company Builds on Spatial Platform Momentum – San Diego Biotechnology NetworkSingular Genomics appointed John Stark as CEO on April 28, 2026. The transition follows the launch of its spatial platform and marks the company's next phase. The announcement was made via PRNewswire.PR NewswireSingular Genomics Launches G4X™ Spatial Research Challenge with Award of Spatial Multiomics Study up to 1,000-SamplesSingular Genomics announced the launch of the G4X Spatial Research Challenge, a program offering a flagship award for an in situ multiomic study of up to 1,000 samples to be conducted on its G4X platform. The challenge is designed for oncology and translational research applications, enabling researchers to pursue multimodal spatial studies at cohort scale with up to 1,000-plex RNA, 16-plex protein, and fH&E analysis per sample. Proposals must be submitted by May 22nd, with a secondary category also available for 3D reconstruction projects from serial FFPE sections.PR NewswireSingular Genomics and Vanderbilt University Medical Center Establish Center of Excellence to Advance High-Throughput Spatial Multimodal Profiling in Gastric Pre-CancerSingular Genomics announced a collaboration with Vanderbilt University Medical Center to establish a Center of Excellence that will deploy the G4X Spatial Sequencer in support of HTAN's Pre-Gastric Cancer program (GAME3D). The partnership aims to enable scalable, cost-efficient spatial multimodal profiling for building comprehensive 3D atlases of gastric disease progression from precancerous lesions to malignancy. The G4X platform will provide integrated in situ readouts combining 1,000-plex RNA, 18-plex protein, and fH&E at subcellular resolution to support longitudinal and heterogeneous clinical specimen analysis.SdbnSingular Genomics and Vanderbilt University Medical Center Establish Center of Excellence to Advance High-Throughput Spatial Multimodal Profiling in Gastric Pre-Cancer – San Diego Biotechnology NetworSingular Genomics and Vanderbilt University Medical Center announced the establishment of a Center of Excellence focused on high-throughput spatial multimodal profiling in gastric pre-cancer research. The collaboration will deploy Singular Genomics' G4X™ platform and support HTAN's Pre-Gastric Cancer program to enable scalable generation of multimodal 3D atlases.PR NewswireSingular Genomics Names the Spatial Technologies Unit at Beth Israel Deaconess Medical Center a G4X™ Center of ExcellenceSingular Genomics announced the designation of the Spatial Technologies Unit at Beth Israel Deaconess Medical Center as a G4X Center of Excellence, building on the unit's role as the first G4X Early Access Program site. The partnership aims to help researchers run reproducible G4X studies at scale by sharing best-practice workflows spanning tissue preparation to data QC, study design, and downstream analysis. The G4X Spatial Sequencer, which enables integrated in situ readout of 1,000-plex RNA, 18-plex protein, and fH&E morphology on up to 128 FFPE samples per run, was commercially launched in the US in February 2026.GenomeWebAGBT: Spatial Biology Field 'Maturing' as Updates Well-Received, if Not FlashyAt the Advances in Genome Biology and Technology (AGBT) general meeting, around half a dozen spatial biology companies announced platform updates and product launches, including Bruker showcasing two new platforms (PaintScape and CellScape) acquired from NanoString Technologies, and Stellaromics formally launching its Pyxa 3D spatial transcriptomics platform with first shipments in April. Several firms such as 10x Genomics were notably subdued at the event, while the field was described as "maturing" by industry experts who noted less flashy but practically significant developments like quality control assays. Illumina, Element Biosciences, and Singular Genomics also advanced their sequencing-based spatial methods, with Illumina claiming its spatial transcriptomics assay detected twice as many significantly expressed genes as a competitor's 5,000-gene panel.PR NewswireSingular Genomics at AGBT 2026: Population-Scale Spatial Takes Center Stage G4X Launch, SPOT-Met InitiativeSingular Genomics launched its G4X high-throughput in situ multiomics platform at AGBT 2026, accompanied by validation data from analysis of approximately 4 billion single cells across nearly 20,000 FFPE samples. Weill Cornell Medicine researchers presented SPOT-Met, a 1,000-tumor colorectal cancer program described as perhaps the world's largest colorectal cancer spatial multiomics initiative, which will leverage the G4X platform. The company also showcased expanded capabilities including a 1,300-gene plex RNA panel with simultaneous assessment of 18 proteins and fH&E, and previewed Direct-Seq in situ sequencing from FFPE samples with Early Access planned for H2 2026.